Skip to main content
Fig. 7 | Journal of Translational Medicine

Fig. 7

From: Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

Fig. 7

Graphical summary of the study main results. a) GCNT3 and Mucin expression increase throughout the IPMN from Low-grade IPMN to High-grade IPMN and PDAC. b O-glycosilated Mucins shield the tumor cells from T cells improving immune escape. c Talniflumate abrogates GCNT3 activity and impairs teh enzyme expression together with MUC1 and MUC5AC favoring T cell recognition and activation

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us